1. Medtech Insight
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Prostate Screening: UK Industry Body Explores Role In Study, Points To Growing Diagnostics Remit

ABHI promises more activity to support early diagnosis and population health management

 
• By Ashley Yeo

Early diagnosis information is central to disease detection and will reduce treatment costs overall, says Nishan Sunthares, who heads the Association of British HealthTech Industries’ work on diagnostic technologies including IVDs.

In fall 2023, the charity Prostate Cancer UK announced it will lead a major screening program starting this year. With funding of £42m ($53m), including a government contribution of £16m, the Transform study is described as the biggest UK prostate cancer diagnosis trial in 20 years. It will begin recruiting in fall 2024.

Transform will investigate promising tests with a goal of providing definitive evidence on the best ways to screen for prostate...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from United Kingdom

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By Marion Webb

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 
• By Natasha Barrow

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

UK MHRA Takes Stock, Seeks CMSO And Reveals Device Innovation Early Access Thinking

 
• By Ashley Yeo

Evolution of the MHRA and its offering to medtechs continues, with the hunt for a visionary chief medical and scientific officer and release of outline plans on early access to innovative devices, building on IDAP learnings.

More from Europe

Swiss Medtech To Battle ‘Arbitrary’ 39% US Tariff

 
• By Ashley Yeo

In return for building a successful US export business, Switzerland has been handed a 39% tariff effective immediately by the Trump administration. Diplomatic channels have been reopened to undo the tariff. Meanwhile, the medtech industry is looking to develop OUS markets for Swiss exporters.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By Marion Webb

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.

US Puts 15% Tariff On EU Exports But Medtechs Push ‘Zero For Zero’

 
• By Ashley Yeo

The US’ foreign trading partners are not working hard enough to secure bilateral deals, says US President Donald Trump, who will introduce new reciprocal tariffs on Aug. 7. MedTech Europe stresses that patients will suffer if medtech is not excluded from the tariffs.